While I hope that is true.....it will be critical to see how many doses the company can scale, the pricing - I’m not sure $70k is sustainable over the longer term and what royalties are assumed. Wombat did some great analysis. It’s a static one since you cannot do more here, but highly insightful.
If the results are FDA yes for aGVHD and the results we hope for ARDS then the method of manufacture- ie partnerships with royalty, will depend on how much we get. It could be less.
genuinely hope though, that your number is on the low side
Mesoblast $200 is possible, page-2
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |